beta

BCAB

BioAtla Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.

Market Cap: 136 Million

Primary Exchange: NASDAQ

Website: bioatla.com

Shares Outstanding: 47.9 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.8288925624218875

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 981 trading days

From: 2021-03-18 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud